Telix Pharmaceuticals Limited Stock Total Asset
| TLX Stock | 15.76 0.16 1.03% |
Telix Pharmaceuticals Limited fundamentals help investors to digest information that contributes to Telix Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Telix Stock. The fundamental analysis module provides a way to measure Telix Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telix Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 398.3 M | 253.4 M | |
| Intangibles To Total Assets | 0.28 | 0.29 |
Telix | Total Asset |
Telix Pharmaceuticals Limited Company Total Asset Analysis
Telix Pharmaceuticals' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Telix Pharmaceuticals Total Asset | 398.3 M |
Most of Telix Pharmaceuticals' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telix Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Telix Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Telix Pharmaceuticals is extremely important. It helps to project a fair market value of Telix Stock properly, considering its historical fundamentals such as Total Asset. Since Telix Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Telix Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Telix Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Telix Total Asset Historical Pattern
Today, most investors in Telix Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Telix Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Telix Pharmaceuticals total asset as a starting point in their analysis.
Telix Pharmaceuticals Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Telix Total Assets
Total Assets |
|
Based on the latest financial disclosure, Telix Pharmaceuticals Limited has a Total Asset of 398.3 M. This is 94.7% lower than that of the Healthcare sector and 79.84% lower than that of the Biotechnology industry. The total asset for all United States stocks is 98.65% higher than that of the company.
Telix Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telix Pharmaceuticals' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Telix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Telix Pharmaceuticals by comparing valuation metrics of similar companies.Telix Pharmaceuticals is currently under evaluation in total asset category among its peers.
Telix Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Telix Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Telix Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Telix Fundamentals
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 5.17 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Number Of Shares Shorted | 8.78 K | ||||
| Price To Book | 20.50 X | ||||
| Price To Sales | 8.17 X | ||||
| Revenue | 496.66 M | ||||
| EBITDA | 22.97 M | ||||
| Net Income | 5.21 M | ||||
| Total Debt | 17.45 M | ||||
| Book Value Per Share | 1.21 X | ||||
| Short Ratio | 0.16 X | ||||
| Earnings Per Share | 0.09 X | ||||
| Target Price | 20.72 | ||||
| Beta | 2.38 | ||||
| Market Capitalization | 5.28 B | ||||
| Total Asset | 398.3 M | ||||
| Retained Earnings | (263.67 M) | ||||
| Working Capital | 67.44 M | ||||
| Net Asset | 398.3 M |
About Telix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telix Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telix Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.